Yervoy and Thrombophlebitis - a phase IV clinical study of FDA data

Summary:

Thrombophlebitis is reported as a side effect among people who take Yervoy (ipilimumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Opdivo, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Thrombophlebitis when taking Yervoy. It is created by eHealthMe based on reports of 26,647 people who have side effects when taking Yervoy from the FDA, and is updated regularly.

What is Yervoy?

Yervoy has active ingredients of ipilimumab. eHealthMe is studying from 26,662 Yervoy users. Check the latest studies of Yervoy.

What is Thrombophlebitis?

Thrombophlebitis (swelling (inflammation) of a vein caused by a blood clot) is found to be associated with 941 drugs and 1,267 conditions by eHealthMe. Check the latest studies of Thrombophlebitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

26,647 people reported to have side effects when taking Yervoy.
Among them, 20 people (0.08%) have Thrombophlebitis.

Among these 20 people:

How long have people been on Yervoy when they have Thrombophlebitis? *

What is the gender of people who have Thrombophlebitis when taking Yervoy? *

female: 30 %
male: 70 %

What is the age of people who have Thrombophlebitis when taking Yervoy? *

What are other drugs people take besides Yervoy? *

What are other side effects people have besides Thrombophlebitis? *

Rashes (redness): 8 people, 40.00%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4 people, 20.00%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 20.00%
Nausea (feeling of having an urge to vomit): 4 people, 20.00%
Faeces Discolored: 3 people, 15.00%
Nausea And Vomiting: 3 people, 15.00%
Drug Ineffective: 3 people, 15.00%
Subclavian Vein Thrombosis (abnormal condition in which a clot develops within the subclavian or axillary vein): 3 people, 15.00%
Anaemia (lack of blood): 3 people, 15.00%
Renal Impairment (severely reduced kidney function): 3 people, 15.00%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 10 people, 50.00%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 8 people, 40.00%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 15.00%

* Approximation only. Some reports may have incomplete information.

Do you take Yervoy and have Thrombophlebitis?

- Check whether Thrombophlebitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Yervoy:

Yervoy (26,662 reports)

Thrombophlebitis treatments and more:

Thrombophlebitis (13,501 reports)

Browse all side effects of Yervoy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thrombophlebitis:

Thrombophlebitis (941 drugs)

Browse all the conditions that are associated with Thrombophlebitis:

Thrombophlebitis (1,267 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ipilimumab (the active ingredients of Yervoy) and Yervoy (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.